Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can play a role in preventing recurrent vascular events from ischemic heart disease patients, whose mechanism consists in not only the reduction of serum lipid level but also anti-inflammatory effects. Serum high sensitive CRP is known to be a predictor of cardiovascular events independent of other conventional risk factors. The present substudy examine whether such pleiotrophic effect of HMG-CoA reductase inhibitor (statin) which decreases high sensitive CRP would be observed in the post-ischemic stroke patients who have already been registered in the J-STARS, and the relationship the values of high sensitive CRP and recurrence of stroke.
- Pravastatin (Pravachol®)Drug
Intervention Desc: HMG-CoA reductase inhibitor; lowers cholesterol
- Statin Drug
Other Names: Atorvastatin, Pitavastain, Rosuvastatin ARM 1: Kind: Experimental Label: Pravastatin
- Allocation: Randomized
- Masking: Open Label
- Purpose: Prevention
- Endpoint: Efficacy Study
- Intervention: Parallel Assignment
Subject already enrolled in J-STARS and has had a lipid profile prior to being on a statin drug. Able to come into clinic for follow-up.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Serum level of high sensitive CRP.|
|Primary||serum level of high sensitive CRP||until the last day of the next February after 5-year follow-up survey|
|Secondary||recurrent stroke||until the last day of the next February after 5-year follow-up survey|